Potential conflict of interest: Dr. Bonkovsky consults, advises, and received grants from Clinuvel. He consults and advises Alnylam and Recordati. He received grants from Vertex. Dr. Fontana consults for GlaxoSmithKline and received grants from Bristol-Myers Squibb, Gilead, Janssen, and Vertex. Dr. Reddy advises and received grants from Merck, Gilead, AbbVie, Bristol-Myers Squibb, Vertex, and Janssen. He advises Genentech-Roche and received grants from Genfit.
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Article first published online: 25 AUG 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 4, pages 1399–1408, October 2014
How to Cite
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, K. R., Seeff, L. B., Serrano, J., Sherker, A. H., Stolz, A., Talwalkar, J., Vega, M. and Vuppalanchi, R. (2014), Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology, 60: 1399–1408. doi: 10.1002/hep.27317
The Drug Induced Liver Injury Network (DILIN) is a cooperative network funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). See the DILIN website (https://dilin.dcri.duke.edu/publications-1) for a complete listing of funding sources, sites, investigators, coinvestigators, coordinators, and staff.
- Issue published online: 22 SEP 2014
- Article first published online: 25 AUG 2014
- Accepted manuscript online: 12 JUL 2014 06:30AM EST
- Manuscript Accepted: 10 JUL 2014
- Manuscript Received: 13 MAR 2014
The Drug-Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by conventional medications as well as herbals and dietary supplements (HDS). To characterize hepatotoxicity and its outcomes from HDS versus medications, patients with hepatotoxicity attributed to medications or HDS were enrolled prospectively between 2004 and 2013. The study took place among eight U.S. referral centers that are part of the DILIN. Consecutive patients with liver injury referred to a DILIN center were eligible. The final sample comprised 130 (15.5%) of all subjects enrolled (839) who were judged to have experienced liver injury caused by HDS. Hepatotoxicity caused by HDS was evaluated by expert opinion. Demographic and clinical characteristics and outcome assessments, including death and liver transplantation (LT), were ascertained. Cases were stratified and compared according to the type of agent implicated in liver injury; 45 had injury caused by bodybuilding HDS, 85 by nonbodybuilding HDS, and 709 by medications. Liver injury caused by HDS increased from 7% to 20% (P < 0.001) during the study period. Bodybuilding HDS caused prolonged jaundice (median, 91 days) in young men, but did not result in any fatalities or LT. The remaining HDS cases presented as hepatocellular injury, predominantly in middle-aged women, and, more frequently, led to death or transplantation, compared to injury from medications (13% vs. 3%; P < 0.05). Conclusions: The proportion of liver injury cases attributed to HDS in DILIN has increased significantly. Liver injury from nonbodybuilding HDS is more severe than from bodybuilding HDS or medications, as evidenced by differences in unfavorable outcomes (death and transplantation). (Hepatology 2014;60:1399–1408)